FMP
Sep 10, 2021 7:15 PM - Davit Kirakosyan
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares were trading around 50% lower today following the company’s mixed top-line results from its Phase 3 DERBY and OAKS studies of pegcetacoplan in geographic atrophy (GA).
Analysts at Oppenheimer lowered their price target on the company’s shares to $65 from $80, adjusting its model, which incorporates an updated PoS of 75% in the US for GA (from 60% previously), but moderate their estimates for potential sales and timing of approval (1H22 FDA filing, ~one year delay in EU). The brokerage awaits additional assessment of these data (Retina Society meeting 09/29-10/02) and feedback from the agency.
Sep 11, 2023 12:38 PM - Rajnish Katharotiya
Price to Earnings is one of the key metrics use to value companies using multiples. The P/E ratio and other multiples are relative valuation metrics and they cannot be looked at in isolation. One of the problems with the P/E metric is the fact that if we are in the peak of a business cycle, earni...
Sep 11, 2023 12:46 PM - Rajnish Katharotiya
One of the key aspects to do well in the stock market is to know what is business risk. It is important to understand what type of business risks a company may have. Photo by Pixabay on Pexels What Is A Business Risk? Investopedia provides a very simple definition of business risk. Busin...
Sep 11, 2023 12:49 PM - Rajnish Katharotiya
Price-to-Earnings ratio is a relative valuation tool. It is used by investors to find great companies at low prices. In this post, we will build a Python script to calculate Price Earnings Ratio for comparable companies. Photo by Skitterphoto on Pexels Price Earnings Ratio and Comparable Compa...